Comparison of the efficacy of third-line treatments for metastatic colorectal cancer: A network meta-analysis

被引：0
|
作者：
Taieb, J. [1 ]
Yahiaoui, S. [2 ]
Choucair, E. [3 ]
Yao, W. [4 ]
Hauch, O. [2 ]
机构：
[1] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France
[2] Lab Servier SAS, Global Value Access & Pricing Dept, Suresnes, France
[3] Lab Servier SAS, Med Affairs, Suresnes, France
[4] Servier Pharmaceut, Dept Clin Res, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
60P
引用
下载
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [21] Proactive Transitioning to Third-Line Treatment in Metastatic Colorectal Cancer
    Bekaii-Saab, Tanios S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 5 - 7
  • [22] Optimizing Administration of Third-Line Treatment in Metastatic Colorectal Cancer
    Prager, Gerald W.
    Ducreux, Michel
    Argiles, Guillem
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (12) : 1 - 20
  • [23] Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis
    Fausto Petrelli
    Alessandro Parisi
    Gianluca Tomasello
    Emanuele Mini
    Marcella Arru
    Alessandro Russo
    Ornella Garrone
    Shelize Khakoo
    Raffaele Ardito
    Michele Ghidini
    BMC Gastroenterology, 23
  • [24] Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis
    Petrelli, Fausto
    Parisi, Alessandro
    Tomasello, Gianluca
    Mini, Emanuele
    Arru, Marcella
    Russo, Alessandro
    Garrone, Ornella
    Khakoo, Shelize
    Ardito, Raffaele
    Ghidini, Michele
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [25] Efficacy of apatinib as third-line treatment of advanced colorectal cancer and prognostic analysis
    Wang, Juchao
    Sun, Qiang
    Zhao, Jian
    Li, Zengming
    Kou, Dan
    Qu, Dongxiang
    JOURNAL OF BUON, 2021, 26 (01): : 93 - 100
  • [26] BUDGET IMPACT ANALYSIS OF REGORAFENIB IN THE THIRD-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Zhu, S.
    Liu, J.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
  • [27] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials
    Cao, Meihui
    Zhou, Mingyi
    Zhang, Jingdong
    JOURNAL OF CHEMOTHERAPY, 2020, 32 (04) : 163 - 170
  • [29] Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves
    Obeng-Kusi, Mavis
    Martin, Jennifer R.
    Roe, Denise
    Erstad, Brian L.
    Abraham, Ivo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 923 - 932
  • [30] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
    Ozaslan, Ersin
    Topaloglu, Ulas Serkan
    Inanc, Mevlude
    Erdem, Umut Gokmen
    Demir, Hacer
    Arpaci, Erkan
    Seker, Mehmet Metin
    Karaaga, Mustafa
    Kiziltepe, Melih
    Eker, Baki
    Ozkan, Metin
    JOURNAL OF BUON, 2017, 22 (04): : 863 - 868
12345